Gilead Sciences experienced positive trading momentum driven by a combination of fundamental strength in its core franchises, favorable research updates, and regulatory developments surrounding key therapeutics. Market sentiment around the biopharmaceutical leader has been reinforced by strong momentum following its second-quarter earnings, where base business revenues surpassed expectations due to accelerated growth in its market-leading HIV portfolio, alongside expanding oncology and liver disease sales. Management raised full-year sales growth guidance for its HIV franchise, signaling robust commercial execution for key therapies like Biktarvy and the rapid adoption of twice-yearly injectable formulations like Yeztugo.

Adding to…